Table 1.
Liver SABR prospective trials.
| Study | Study Type | Patient # | Lesion # | Primary Histology | Dose (Gy)/ Fraction Number |
BED (a/b = 10) | Toxicity | Local Tumor Control | Overall Survival |
|---|---|---|---|---|---|---|---|---|---|
| Herfarth et al. [42] | Phase I/II | 37 | 60 | Mixed | 14-26/1 | 33–94 | 71% @ 1 year | 72% @ 1 year | |
| Mendez–Romero et al. [43] | Phase I/II | 17 | 39 | Mixed | 37.5/3 | 84 | 12% G3 Liver | 100% @ 1 year 86% @ 2 years |
85% @ 1 year 62% @ 2 years |
| Rusthoven et al. [44] | Phase I/II | 47 | 63 | Mixed | 36–60/3 | 79–180 | 1.5% G3 (dermatitis) | 95% @ 1 year 92% @ 2 years |
30% @ 2 years |
| Lee et al. [45] | Dose escalation, phase I | 68 | 142 | Mixed | 28–60/6 | 41–120 | 10% G3+ | 71% @ 1 year | 47% @ 1.5 years |
| Rule et al. [46] | Dose escalation, phase I | 27 | 37 | Mixed | 30/3–50–60/5 | 60–132 | 4% G3 Liver | 100%, 89%, 56% * @ 2 years | 50%, 67%, 56% * @ 2 years |
| Comito et al. [47] | Observational | 42 | 52 | Colorectal | 75/3 | 263 | 60% G2, 0%G3 | 95% @ 1 year 85% @ 2 years |
85% @ 1 year 65% @ 2 years |
| Scorsetti et al. [48] | Phase II | 42 | 52 | Colorectal | 75/3 | 263 | 25% G2 Liver, 0% G3 | 95% @ 1 year 91% @ 2 years 85% @ 3 years |
65% @ 2 years |
| Goodman et al. [49] | Dose escalation, phase I | 26 | 40 | Mixed | 18–30/1 | 50–120 | 8% GI bleeding | 77% @ 1 year | 50% @ 2 years |
| Meyer et al. [50] | Dose escalation, phase I | 14 | 17 | Mixed | 35–40/1 | 158–200 | 6% G2 | 100% @ 2.5 years | 78% @ 2 years |
| Hong et al. [51] | Phase II | 89 | 143 | Mixed | 30–50/5 | 48–100 | No G3+ | 72% @ 1 year 61% @ 3 years |
66% @ 1 year 21% @ 3 years |
| Scorsetti et al. [52] | Phase II | 61 | 76 | Mixed | 75/3 | 263 | 2% G3 chest wall pain | 94% @ 1 year 78% @ 3 years 78% @ 5 years |
85% @ 1 year 31% @ 3 years 18% @ 5 years |
| Kang et al. [53] | Phase I | 9 | 14 | Mixed | 36–60/3 | 79–180 | No G3+ | NR | NR |
| Dawson et al. [54] | Dose escalation, phase I, multicenter | 26 | 37 | Mixed | 35–50/10 | 47–75 | 7.7% G3 GI | NR | NR |
# = number, cm = centimeter, BED = biologically effective dose, Gy = Gray, NR = not reported, GI = gastrointestinal, G3 = grade 3, G2 = grade 2, @ = at, * = 60 Gy/12 Gy per fraction, 50 Gy/10 Gy per fraction, and 30 Gy/10 Gy per fraction dose cohorts.